원료의약품 CDMO 시장 : 제품별, 적응증별, 약제별, 워크플로우별, 용도별, 최종 용도별 - 세계 예측

Global Active Pharmaceutical Ingredient CDMO Market size is predicted to record 6.6% CAGR from 2024 to 2032, due to the surging R&D initiatives amidst the increasing demand for generic drugs. These organizations are innovating active pharmaceutical ingredient API synthesis and process optimization to enhance drug efficacy and production efficiency.

The rising demand for generic drugs is also driving CDMOs to expand their capabilities and capacities to meet the global pharmaceutical needs. Growing efforts on developing cost-effective and high-quality APIs for leveraging advanced technologies like continuous manufacturing and green chemistry will drive the industry growth. For instance, in March 2022, Sumitomo Chemical Co., Ltd. announced the construction of a new manufacturing plant for APIs, scheduled to come on stream in September 2024, to enhance its capacity to supply high-quality APIs and intermediates for small molecule drugs.

The active pharmaceutical ingredient CDMO market is segregated into product, indication, drug, workflow, application, end-use, and region.

By product, the biological APIs segment is estimated to rise at a significant rate from 2024 to 2032, due to the growing demand for biologic drugs. CDMO's are leveraging advanced biotechnological processes to manufacture complex biological molecules, such as monoclonal antibodies and recombinant proteins. There have also been innovations in bio-processing techniques to improve yields, purity, and scalability of biological APIs.

Active pharmaceutical ingredient CDMO industry from the veterinary application segment is expected to expand from 2024 to 2032 owing to the strong need for addressing the increasing need for effective animal health products. This has led to the higher development and manufacturing of APIs specifically for veterinary medicines including antibiotics, anti-parasitic, and vaccines. API CDMOs also leverage advanced technologies to improve the efficacy and safety of veterinary drugs.

Regionally, the Europe active pharmaceutical ingredient CDMO industry size is projected to witness robust growth between 2024 and 2032, propelled by the globalization of pharmaceutical supply chains and stringent regulatory compliance requirements. CDMO's in the region are enhancing their manufacturing processes to ensure the seamless integration of APIs into global supply chains for meeting the diverse international standards. Surging adoption of advanced technologies and practices to maintain high-quality production standards will drive the market growth in Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of chronic disease
    • 3.2.1.2 Rising R&D activities in the pharmaceutical industry
    • 3.2.1.3 Rising demand for generic drugs
    • 3.2.1.4 Rising adoption of outsourcing services
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory compliance
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Company positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Chemical APIs
• 5.3 Biological APIs
• 5.4 High potent APIs

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oncology
• 6.3 Cardiovascular diseases
• 6.4 Diabetes
• 6.5 Hormonal disorders
• 6.6 Infectious diseases
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Drug, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generic

Chapter 8 Market Estimates and Forecast, By Workflow, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Clinical
• 8.3 Commercial

Chapter 9 Market Estimates and Forecast, By Application 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Human application
• 9.3 Veterinary application

Chapter 10 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Pharmaceutical & biotech companies
• 10.3 Academic and research institutes

Chapter 11 Market Estimates and Forecast, By Region, 2021- 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 The Netherlands
  • 11.3.7 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE
  • 11.6.4 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Ajinomoto Biopharma Services
• 12.2 Boehringer Ingelheim
• 12.3 Cambex Corporation
• 12.4 Catalent, Inc.
• 12.5 CordenPharma International
• 12.6 Kymanox Corporation
• 12.7 Lonza AG
• 12.8 Primal Pharma Solutions
• 12.9 Recipharm AB
• 12.10 Samsung Biologics
• 12.11 Siegfried Holding AG
• 12.12 Thermo Fisher Scientific Inc.